Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2021 February;112(1) > Minerva Medica 2021 February;112(1):20-30

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  ENDOMETRIAL CANCER 

Minerva Medica 2021 February;112(1):20-30

DOI: 10.23736/S0026-4806.20.07082-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Histomolecular features of high-grade endometrial cancers

Matteo MOROTTI 1 , Hooman SOLEYMANI MAJD 1, Jvan CASARIN 2, Moiad ALAZZAM 1, Stephen DAMATO 3

1 Department of Gynecological Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, UK; 2 Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy; 3 Department of Cellular Pathology, Oxford University Hospitals, Oxford, UK



High-grade endometrial cancers (ECs) are an aggressive subset of ECs accounting for 70-80% of EC-related deaths. Currently, staging surgery, together with chemotherapy or radiotherapy, is the primary treatment strategy for these cancers. The widespread use of next-generation sequencing has led to a refined understanding of EC’s genomics with important information for diagnosis and therapy for individual patients (precision medicine). However, advances in the genomics assessment of high-grade tumors have been slower due to their lower incidence than low-grade EC. This article will briefly introduce the current state of knowledge of the genomics of G3 endometrioid EC, serous uterine cancer, clear cell uterine carcinoma and uterine carcinosarcoma and discuss its implications for diagnosis and targeted therapy.


KEY WORDS: Endometrial neoplasms; Genomics; Molecular targeted therapy

top of page